Therapeutic options in the treatment of nighttime gastroesophageal reflux

Digestion

Volumn 72, Issue 4, 2005, Pages 229-238

  Orr, William C ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Lynn Health Sciences Institute   (United States)

Author keywords

GERD; Nocturnal gastroesophageal reflux disease; Proton pump inhibitors; Sleep

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACID SECRETION; ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL REFLUX; HEARTBURN; HUMAN; NIGHT; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RESPIRATORY TRACT DISEASE; RISK FACTOR; SLEEP APNEA SYNDROME; SLEEP DISORDER;

CIRCADIAN RHYTHM; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; SLEEP; TREATMENT OUTCOME;

EID: 29244480018     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089957     Document Type: Article

References (52)

1. Farup C, Kleinman L, Sloan S, et al: The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161:45-52.
2. Shaker R, Castell DO, Schoenfeld PS, et al: Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-1493.
3. Ing AJ, Ngu MC, Breslin AB: Obstructive sleep apnea and gastroesophageal reflux. Am J Med 2000;108(suppl 4a):120S-125S.
4. Penzel T, Becker HF, Brandenburg U, et al: Arousal in patients with gastro-oesophageal reflux and sleep apnoea. Eur Respir J 1999;14:1266-1270.
5. Harding SM: Nocturnal asthma: role of nocturnal gastroesophageal reflux. Chronobiol Int 1999;16:641-662.
6. Hanson DG, Jiang JJ: Diagnosis and management of chronic laryngitis associated with reflux. Am J Med 2000;108(suppl 4a):112S-119S.
7. Gunnbjornsdottir MI, Omenaas E, Gislason T, et al: The RHINE Study Group. Obesity and nocturnal gastro-oesophageal reflux are related to onset of asthma and respiratory symptoms. Eur Respir J 2004;24:116-121.
8. Sontag SJ, O'Connell S, Miller TQ, et al: Asthmatics have more nocturnal gasping and reflux symptoms than no asthmatics, and they are related to bedtime eating. Am J Gastroenterol 2004;99:789-796.
9. Sontag SJ, O'Connell S, Khandelwal S, et al: Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990;99:613-620.
10. Fass R, Achem SR, Harding S, et al: Review article: supra-oesophageal manifestations of gastro-oesophageal reflux disease and the role of night-time gastro-oesophageal reflux. Aliment Pharmacol Ther 2004;20(suppl 9):26-38.
11. Lagergren J, Bergstrom R, Lindgren A, et al: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
12. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991265:1287-1289.
13. Pellegrini CA, DeMeester TR, Johnson LF, et al: Gastroesophageal reflux and pulmonary aspiration: incidence, functional abnormality, and results of surgical therapy. Surgery 1979;86:110-119.
14. Ruth M, Carlsson S, Mansson I, et al: Scintigraphic detection of gastro-pulmonary aspiration in patients with respiratory disorders. Clin Physiol 1993;13:19-33.
15. Freidin N, Fisher MJ, Taylor W, et al: Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut 1991;32:1275-1279.
16. Orr WC: Sleep issues in gastroesophageal reflux disease: beyond simple heartburn control. Rev Gastroenterol Disord 2003;3(suppl 4):S22-S29.
17. Orr WC, Allen ML, Robinson M: The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994;89:509-512.
18. Dhiman RH, Saraswat VA, Mishra A, Naik SR: Inclusion of supine period in short-duration pH monitoring is essential in diagnosis of gastroesophageal reflux disease. Dig Dis Sci 1996;41:764-772.
19. Orr WC, Johnson LF, Robinson MG: Effect of sleep on swallowing, esophageal peristalsis, and acid clearance. Gastroenterology 1984;86:814-819.
20. Johnson LF, Harmon JW: Experimental esophagitis in a rabbit model: clinical relevance. J Clin Gastroenterol 1986;8(suppl 1):26-44.
21. Xenos ES: The role of esophageal motility and hiatal hernia in esophageal exposure to acid. Surg Endosc 2002;16:914-920.
22. Fouad YM, Katz PO, Castell DO: Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999;13:1467-1471.
23. Khoury RM, Camacho-Lobato L, Katz PO, et al: Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999;94:2069-2073.
24. Orr WC, Harnish MJ: Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther 1998;12:1033-1038.
25. Galmiche JP, Letessier E, Scarpignato C: Treatment of gastro-oesophageal reflux disease in adults. BMJ 1998;316:1720-1723.
26. Chiba N, De Gara CJ, Wilkinson JM, et al: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810.
27. Richter JE, Bochenek W: Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000;95:3071-3080.
28. Richter JE, Kovacs TO, Greski-Rose PA, et al: Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999;13:795-804.
29. Fraser AG, Sawyerr AM, Hudson M, et al: Morning versus evening dosing of lansoprazole 30 mg daily on 24-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996;10:523-527.
30. Miner P Jr, Orr W, Filippone J, et al: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-1339.
31. Kahrilas P, Miner P, Mao L, et al: Effective control of heartburn with rabeprazole in endoscopically negative GERD (abstract). Am J Gastroenterol 2002;97(suppl S25):489.
32. Robinson M, Fitzgerald S, Hegedus R, et al: Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-454.
33. Kahrilas P, Miner P, Johanson J, et al: Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005, in press.
34. Pehlivanov ND, Olyaee M, Sarosiek I, et al: Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003;18:883-890.
35. Hatlebakk JG, Katz PO, Kuo B, et al: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
36. Hammer J, Schmidt B: Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004;19:1105-1110.
37. Adachi K, Komazawa Y, Fujishiro H, et al: Nocturnal gastric acid breakthrough duringthe administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol 2003;38:830-835.
38. Shimatani T, Inoue M, Kuroiwa T, et al: Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 200419:113-122.
39. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology, 1998;115:1335-1339.
40. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-767.
41. Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-550.
42. Orr WC, Harnish MJ: Efficacy of omeprazole twice daily with supplemental H: blockade at bedtime in the suppression of nocturnal esophageal and gastric acidity. Aliment Pharmacol Ther 2003;17:1553-1558.
43. Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003;18:587-594.
44. Kahrilas PJ, Falk GW, Johnson DA, et al: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-1258.
45. Castell DO, Kahrilas PJ, Richter JE, et al: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-583.
46. Bruley des Varannes S, Gharib H, Bicheler V, et al: Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double-blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 2004;20:899-907.
47. Williams MP, Sercombe J, Hamilton MI, et al: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-1089.
48. Holtmann G, Bytzer P, Metz M, et al: A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-485.
49. Pantoflickova D, Dorta G, Ravic M, et al: Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507-1514.
50. Warrington S, Baisley K, Boyce M, et al: Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-hour intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002;16:1301-1307.
51. Baisley K, Warrington S, Tejura B, et al: Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gut 2002;50:A63.
52. Miner P Jr, Katz PO, Chen Y, et al: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-2620.